+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report by Drug Class (Beta Blockers, Sodium Channel Blockers), Route of Administration (Oral, Parenteral), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 6024570
Description Jump to:
The global antiarrhythmic drugs market size is anticipated to reach USD 1.62 billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030. This anticipated growth is driven by multiple interrelated factors, including the rising prevalence of cardiovascular diseases (CVDs), an aging global population, advancements in drug development, regulatory support, and government initiatives aimed at improving cardiovascular health.According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for approximately 17.9 million deaths annually.

Furthermore, the aging population is a significant factor contributing to market expansion. The U.S. Census Bureau reports that by 2030, approximately 20% of the U.S. population will be 65 years or older. This demographic shift is expected to lead to an increase in cardiovascular conditions, including arrhythmias, thereby heightening the demand for antiarrhythmic drugs. As people age, their risk of developing heart conditions increases, necessitating ongoing treatment and management strategies. This trend is not limited to the U.S.; many developed and developing nations are experiencing similar demographic changes, resulting in a global increase in demand for antiarrhythmic therapies.

Recent advancements in drug development are further propelling market growth. Research and innovation in the field of antiarrhythmic drugs have led to the introduction of novel compounds and therapeutic approaches. For instance, the development of new drug formulations that target specific ion channels has improved the efficacy and safety profiles of these medications. Moreover, advances in personalized medicine and pharmacogenomics are paving the way for tailored treatment strategies that optimize drug efficacy based on individual patient profiles. Such innovations not only enhance treatment outcomes but also encourage the adoption of antiarrhythmic therapies among healthcare providers.

Antiarrhythmic Drugs Market Report Highlights

  • By drug class, the beta blockers segment accounted for the largest revenue share of 34.7% in 2023. Their efficacy in reducing heart rate and controlling blood pressure has made them a cornerstone in the treatment of these disorders.
  • Based on route of administration, the oral segment accounted for the largest revenue share of around 65.0% in 2023. Oral formulations allow patients to self-administer treatments at home, eliminating the need for invasive procedures or hospital visits, which can be particularly appealing in managing chronic conditions such as atrial fibrillation and ventricular tachycardia.
  • Based on distribution channels, the hospital pharmacies segment accounted for the largest revenue share of around 55.0% in global market for antiarrhythmic drugs in 2023.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Antiarrhythmic Drugs market include:

  • Pfizer
  • Novartis
  • Mylan (now part of Viatris)
  • Baxter International
  • Sanofi
  • GlaxoSmithKline
  • Mayne Pharma
  • Upsher-Smith Laboratories
  • Amomed Pharma
  • Merck


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Route of Administration
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class Outlook
2.2.2. Route of Administration
2.2.3. Distribution Channel
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Antiarrhythmic Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Prevalence of Cardiovascular Diseases
3.2.1.2. Advancements in Drug Development
3.2.2. Market restraint analysis
3.2.2.1. High Drug Class Cost
3.2.2.2. Competition from Alternative Therapies
3.3. Antiarrhythmic Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Antiarrhythmic Drugs Market: Drug Class Estimates & Trend Analysis
4.1. Antiarrhythmic Drugs Market: Drug Class Dashboard
4.2. Antiarrhythmic Drugs Market: Drug Class Movement Analysis
4.3. Antiarrhythmic Drugs Market by Drug Class, Revenue
4.4. Sodium Channel Blockers
4.4.1. Sodium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Potassium Channel Blockers
4.5.1. Potassium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Calcium Channel Blockers
4.6.1. Calcium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Antiarrhythmic Drugs Market: Route of Administration Estimates & Trend Analysis
5.1. Antiarrhythmic Drugs Market: Route of Administration Dashboard
5.2. Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
5.3. Antiarrhythmic Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
5.4. Oral
5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Parenteral
5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Other
5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Antiarrhythmic Drugs Market: Distribution Channel Estimates & Trend Analysis
6.1. Antiarrhythmic Drugs Market: Distribution Channel Dashboard
6.2. Antiarrhythmic Drugs Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Other
6.5.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Antiarrhythmic Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Route of Administration, and Distribution Channel
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Vendor Landscape
8.2.1. List of key distributors and channel partners
8.2.2. Key company market share analysis, 2023
8.2.3. Pfizer
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Novartis
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Mylan
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Baxter International
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Sanofi
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. GlaxoSmithKline
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Mayne Pharma
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Upsher-Smith Laboratories
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. Amomed Pharma
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Merck
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
List of Tables
Table 1 List Of Abbreviation
Table 2 North America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 3 North America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 4 North America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 5 North America Antiarrhythmic Drugs Market, Distribution Channel, 2018 - 2030 (USD Million)
Table 6 U.S. Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 7 U.S. Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 8 U.S. Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 9 Canada Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 10 Canada Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 11 Canada Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Mexico Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 Mexico Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 14 Mexico Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 15 Europe Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 16 Europe Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 17 Europe Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 18 Europe Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Germany Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 Germany Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Germany Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 22 UK Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 23 UK Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 24 UK Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 France Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 France Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 France Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Italy Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 Italy Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 Italy Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 31 Spain Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 32 Spain Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 33 Spain Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Denmark Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 Denmark Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Denmark Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Sweden Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 38 Sweden Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Sweden Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Norway Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 41 Norway Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 42 Norway Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 China Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 48 China Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 49 China Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 50 Japan Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 51 Japan Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 Japan Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 India Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 India Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 55 India Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 56 South Korea Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 57 South Korea Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 58 South Korea Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Australia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 60 Australia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 61 Australia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Thailand Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 63 Thailand Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 64 Thailand Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 65 Latin America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 66 Latin America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 67 Latin America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 68 Latin America Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 69 Brazil Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 70 Brazil Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 71 Brazil Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 72 Argentina Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 73 Argentina Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 74 Argentina Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 75 MEA Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 76 MEA Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 77 MEA Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 78 MEA Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 79 South Africa Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 80 South Africa Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 81 South Africa Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 85 UAE Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 86 UAE Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 87 UAE Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 88 Kuwait Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 89 Kuwait Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 90 Kuwait Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Antiarrhythmic Drugs Market: Market Outlook
Fig. 14 Antiarrhythmic Drugs Competitive Insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Antiarrhythmic Drugs Market Driver Impact
Fig. 18 Antiarrhythmic Drugs Market Restraint Impact
Fig. 19 Antiarrhythmic Drugs Market Strategic Initiatives Analysis
Fig. 20 Antiarrhythmic Drugs Market: Drug Class Movement Analysis
Fig. 21 Antiarrhythmic Drugs Market: Drug Class Outlook And Key Takeaways
Fig. 22 Sodium Channel Blockers market estimates and forecast, 2018 - 2030
Fig. 23 Beta Blockers market estimates and forecast, 2018 - 2030
Fig. 24 Potassium Channel Blockers market estimates and forecast, 2018 - 2030
Fig. 25 Calcium Channel Blockers market estimates and forecast, 2018 - 2030
Fig. 26 Other market estimates and forecast, 2018 - 2030
Fig. 27 Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
Fig. 28 Antiarrhythmic Drugs Market: Route of Administration Outlook And Key Takeaways
Fig. 29 Oral market estimates and forecast, 2018 - 2030
Fig. 30 Parenteral market estimates and forecast, 2018 - 2030
Fig. 31 Other market estimates and forecast, 2018 - 2030
Fig. 32 Antiarrhythmic Drugs Market: Distribution Channel Movement Analysis
Fig. 33 Antiarrhythmic Drugs Market: Distribution Channel Outlook And Key Takeaways
Fig. 34 Hospital Pharmacies market estimates and forecast, 2018 - 2030
Fig. 35 Retail Pharmacies market estimates and forecast, 2018 - 2030
Fig. 36 Other market estimates and forecast, 2018 - 2030
Fig. 37 Antiarrhythmic Drugs Market: Regional Movement Analysis
Fig. 38 Antiarrhythmic Drugs Market: Regional Outlook And Key Takeaways
Fig. 39 Antiarrhythmic Drugs market share and leading players
Fig. 40 North America, by country
Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 U.S. key country dynamics
Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Canada key country dynamics
Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Mexico key country dynamics
Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 UK key country dynamics
Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Germany key country dynamics
Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 France key country dynamics
Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Italy key country dynamics
Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Spain key country dynamics
Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Denmark key country dynamics
Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Sweden key country dynamics
Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Norway key country dynamics
Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 China key country dynamics
Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Japan key country dynamics
Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 India key country dynamics
Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Thailand key country dynamics
Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 South Korea key country dynamics
Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Australia key country dynamics
Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Brazil key country dynamics
Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Argentina key country dynamics
Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 South Africa key country dynamics
Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Saudi Arabia key country dynamics
Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 UAE key country dynamics
Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Kuwait key country dynamics
Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Market share of key market players- Antiarrhythmic Drugs market

Companies Mentioned

  • Pfizer
  • Novartis
  • Mylan (now part of Viatris)
  • Baxter International
  • Sanofi
  • GlaxoSmithKline
  • Mayne Pharma
  • Upsher-Smith Laboratories
  • Amomed Pharma
  • Merck

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedOctober 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 1.05 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.62 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Critical Care Antiarrhythmic Drugs Global Market Report 2024 - Product Image

Critical Care Antiarrhythmic Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Sodium channel blockers - Pipeline Insight, 2024 - Product Image

Sodium channel blockers - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Cardiac Arrhythmias Therapeutics - Global Strategic Business Report - Product Image

Cardiac Arrhythmias Therapeutics - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Beta Blockers Market by Type, Application, Distribution Channel - Global Forecast 2025-2030 - Product Image

Beta Blockers Market by Type, Application, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.